(NASDAQ: GLYC) Glycomimetics's forecast annual revenue growth rate of 481.39% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Glycomimetics's revenue in 2024 is $10,000.On average, 1 Wall Street analysts forecast GLYC's revenue for 2025 to be $689,124,564, with the lowest GLYC revenue forecast at $689,124,564, and the highest GLYC revenue forecast at $689,124,564. On average, 1 Wall Street analysts forecast GLYC's revenue for 2026 to be $244,964,766, with the lowest GLYC revenue forecast at $244,964,766, and the highest GLYC revenue forecast at $244,964,766.
In 2027, GLYC is forecast to generate $617,891,389 in revenue, with the lowest revenue forecast at $522,161,737 and the highest revenue forecast at $713,621,041.